Patents by Inventor Brian C. Shook

Brian C. Shook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination pharmaceutical agents as RSV inhibitors
    Patent number: 12268694
    Abstract: The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: April 8, 2025
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Kai Lin, Michael H. J. Rhodin, Nicole V. McAllister, Yat Sun Or
  • COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS
    Publication number: 20250074922
    Abstract: The disclosure relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, and x are defined herein, and pharmaceutical compositions comprising compounds of Formula I, or a pharmaceutically acceptable salt thereof. These compounds and pharmaceutical compositions are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
    Type: Application
    Filed: August 29, 2024
    Publication date: March 6, 2025
    Inventors: Lucrezia De Pascalis, Peng Liu, Brian C. Shook
  • Benzodiazepine Derivatives as RSV Inhibitors
    Publication number: 20240360155
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: February 22, 2024
    Publication date: October 31, 2024
    Inventors: Brian C. SHOOK, In Jong KIM, Thomas P. BLAISDELL, Jianming YU, Joseph D. PANARESE, Yat Sun OR
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 11952389
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 9, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
  • Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
    Patent number: 11919915
    Abstract: The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
    Type: Grant
    Filed: June 27, 2023
    Date of Patent: March 5, 2024
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Lucrezia De Pascalis, Heather Jane Finlay, Sandra King, Zenon D. Konteatis, Brian C. Shook
  • COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS
    Publication number: 20230365592
    Abstract: The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
    Type: Application
    Filed: February 27, 2023
    Publication date: November 16, 2023
    Inventors: Lucrezia De Pascalis, Heather Jane Finlay, Sandra King, Zenon D. Konteatis, Brian C. Shook
  • COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS
    Publication number: 20230339980
    Abstract: The disclosure relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein, m, R1-R5, R5A, and L are defined herein. These compounds are useful in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.
    Type: Application
    Filed: June 27, 2023
    Publication date: October 26, 2023
    Applicant: Agios Pharmaceuticals, Inc.
    Inventors: Lucrezia De Pascalis, Heather Jane Finlay, Sandra King, Zenon D. Konteatis, Brian C. Shook
  • BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
    Publication number: 20230087410
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: May 3, 2022
    Publication date: March 23, 2023
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
  • COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS
    Publication number: 20220323460
    Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
    Type: Application
    Filed: November 10, 2020
    Publication date: October 13, 2022
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Kai Lin, Michael H.J. Rhodin, Nicole V. McAllister, Yat Sun Or
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 11390631
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: July 19, 2022
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 11091501
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Jianming Yu, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Thomas P. Blaisdell, Brian C. Shook, Yat Sun Or
  • Processes for the preparation of benzodiazepine derivatives
    Patent number: 10906895
    Abstract: The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 2, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Brian C. Shook, Yat Sun Or
  • Combination pharmaceutical agents as RSV inhibitors
    Patent number: 10881666
    Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 5, 2021
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Kai Lin, Michael H. J. Rhodin, Nicole V. McAllister, Yat Sun Or
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 10865215
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: December 15, 2020
    Assignee: ENANTA PHARMACEUTICALS, INC.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 10851115
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: December 1, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: In Jong Kim, Joseph Panarese, Thomas P. Blaisdell, Jianming Yu, Brian C. Shook, Yat Sun Or
  • Heterocyclic compounds as RSV inhibitors
    Patent number: 10759816
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: September 1, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jianming Yu, Brian C. Shook, Thomas P. Blaisdell, In Jong Kim, Joseph Panarese, Kevin McGrath, Solymar Negretti-Emmanuelli, Yat Sun Or
  • Aryldiazepine derivatives as RSV inhibitors
    Patent number: 10752598
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: August 25, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Thomas P. Blaisdell, Brian C. Shook, In Jong Kim
  • BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS
    Publication number: 20200223867
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or
  • Azepin-2-one derivatives as RSV inhibitors
    Patent number: 10647711
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 12, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Thomas P. Blaisdell, Brian C. Shook, In Jong Kim, Yat Sun Or
  • Benzodiazepine derivatives as RSV inhibitors
    Patent number: 10570153
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: February 25, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Yat Sun Or